title: Cost effectiveness of the Expert Patients Programme (EPP) for patients with chronic conditions.
abstract: OBJECTIVE
  To assess the cost effectiveness of the Expert Patients Programme (EPP) intervention compared to a treatment as usual alternative.
  
  
  METHODS
  Two-arm pragmatic randomised controlled trial design with waiting list control.
  
  
  METHODS
  Community settings in England.
  
  
  METHODS
  Patients with a wide range of self-defined long-term conditions.
  
  
  METHODS
  The EPP based on the US chronic disease self management program (CDSMP), a lay-led self-care group involving six weekly sessions to teach self-care support skills.
  
  
  METHODS
  Costs estimated over a 6-month period from a societal perspective. Health outcomes estimated in terms of quality adjusted life years (QALYs) generated by patients' response to the EQ5D at baseline and 6-month follow-up.
  
  
  RESULTS
  The intervention group is associated with better patient outcomes, at slightly lower cost. Specifically, the intervention group has a 0.020 QALY gain compared with the control group, and a reduced cost of around 27 pounds per patient. The intervention would therefore be considered dominant. While the QALYs gained are small in absolute terms, an additional 0.02 QALY is equivalent to an extra one week of perfect health per year. When the value of a QALY is 20,000 pounds the EPP has a probability of 94% of being cost effective. Indeed, for all plausible values of willingness-to-pay for a QALY the EPP group is more likely to be cost effective than the control group.
  
  
  CONCLUSIONS
  The EPP intervention evaluated in this trial is very likely to provide a cost effective alternative to usual care in people with long-term conditions.
authors.affiliation: Centre for Health Economics, University of York, Heslington, York, UK.
authors.forename: G
authors.initials: G
authors.lastname: Richardson
authors.forename: A
authors.initials: A
authors.lastname: Kennedy
authors.forename: D
authors.initials: D
authors.lastname: Reeves
authors.forename: P
authors.initials: P
authors.lastname: Bower
authors.forename: V
authors.initials: V
authors.lastname: Lee
authors.forename: E
authors.initials: E
authors.lastname: Middleton
authors.forename: C
authors.initials: C
authors.lastname: Gardner
authors.forename: C
authors.initials: C
authors.lastname: Gately
authors.forename: A
authors.initials: A
authors.lastname: Rogers
mesh_terms: D002908:Chronic Disease / Q000191:economics / Q000628:therapy*; D003362:Cost-Benefit Analysis; D004739:England; D005260:Female; D006295:Health Resources / Q000191:economics / Q000706:statistics & numerical data; D006304:Health Status; D006801:Humans; D008297:Male; D010342:Patient Acceptance of Health Care / Q000706:statistics & numerical data; D019057:Quality-Adjusted Life Years